# MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme

> **NCT00902577** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 50 (actual)

## Conditions studied

- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma

## Interventions

- **DRUG:** FMISO
- **OTHER:** MRI
- **OTHER:** PET
- **OTHER:** MRS

## Key facts

- **NCT ID:** NCT00902577
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08-24
- **Primary completion:** 2018-01-31
- **Final completion:** 2018-01-31
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2019-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00902577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00902577, "MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme". Retrieved via AI Analytics 2026-09-23 from https://api.ai-analytics.org/clinical/NCT00902577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*